3Année·

I think that in an inflationary environment and an environment with rising key interest rates, healthcare & pharma & biotech will outperform. Many stocks are so cheaply valued that the upside is simply much greater than the downside. Wall Street is underinvested in healthcare.

However, when looking for a meaningful ETF on this, I run into difficulties. Practically all ETFs in the sector available in Germany have United Health, Pfizer, Lilly, etc. as their largest position. They are all strongly run and no longer really cheap. That's why I don't really think the healthcare ETFs make sense, because I'm not taking advantage of the undervaluation.

The only ETF that comes close to my criterion is this one. It holds (weighting sorted in descending order):

-Amgen

-Gilead

-Moderna

-Regeneron

-Illumina

-Vertex

-Biogen

-Astra Zeneca

-Seagen

-Biontech

Of these, at least half of the largest stocks are promising and favorable. But unfortunately it is still not optimal. I would love to put together my own ETF as I do with the Semis, but unfortunately I lack the capital lmao.

What are the opinions here? Do you have interesting alternatives?

13 Commentaires

E. coli@Escherichia_coli

3Année

BioNTech must be the strongest position. Ugur! Ugur! Ugur!🦍

•

Moritz@leveragegrinding

3Année

@44Goon

•

Snostrich@Snostrich

3Année

I can also name Novartis. With a forward PE of 12. However, EV/Ebitda is somewhat higher in comparison than at the companies you mentioned

••

dronix111@dronix111

3Année

@Snostrich Novartis is at the top of my watch list. The share is really far too cheap, even from a historical perspective. I came to Bristol Myers with the same thought and it's doing great so far.

•

Nicolas Professioneller Rolls Royce Großaktionär Coole Leute: @leveragegrinding, @SharkAce und @Lorena(aber die ist nen bisschen schüchtern)@getquinfuermerchverkauft

3Année

Isn't there a biotechnology small caps ETF?

••

dronix111@dronix111

3Année

@getquin I don't want small caps. I want the cheaply valued big pharma companies.

••

Nicolas Professioneller Rolls Royce Großaktionär Coole Leute: @leveragegrinding, @SharkAce und @Lorena(aber die ist nen bisschen schüchtern)@getquinfuermerchverkauft

3Année

@dronix111 That makes it quite difficult indeed

••

Utilisateur supprimé

3Année

Le commentaire a été supprimé

dronix111@dronix111

3Année

@Eochaid AZ is overrated? Why do you think that? It's not a vaccine company like Biontech.

The problem is, I hate savings plans. I'm actually an active trader and can therefore handle market techniques and timing quite well and can buy much better myself than a savings plan can. I'm also far too impatient for that.
I would like to have several stocks, preferably an ETF of Amgen, AZ, Novartis, Abbott, J&J, Neurocrine, Regeneron and Biontech. But that's just not possible and so many individual positions with small savings plans are simply garbage. Too impatient, too confusing, I can't time it and the lack of timing means I lose out on returns. You also have to remember that my investment horizon is 1-2 years...

••

Utilisateur supprimé

3Année

Le commentaire a été supprimé

dronix111@dronix111

3Année

@Eochaid Have you looked at AZ's valuation or just the share price performance? The share is very cheaply valued and the vaccine hardly accounts for any of the sales.

••

Utilisateur supprimé

3Année

Le commentaire a été supprimé

dronix111@dronix111

3Année

@Eochaid Huh? I don't think it was an insult wtf 😂 I just wanted to hear your reasoning because I'm interested in the reasons.

And unfortunately I still don't get it. You say AZ is too expensive with the justification that too much vaccine fantasy is priced in. However, the valuation is fundamentally totally favorable and the vaccine accounts for hardly any of their sales. So what exactly is the vaccine fantasy priced in? It is not.

••

Voir une réponse de plus